Rationale: It is now well established that immune responses can take place outside of primary and secondary lymphoid organs. We previously described the presence of tertiary lymphoid structures (TLS) in patients with non-small cell lung cancer (NSCLC) characterized by clusters of mature dendritic cells (DCs) and T cells surrounded by B-cell follicles. We demonstrated that the density of these mature DCs was associated with favorable clinical outcome.
Tumors support a complex microenvironment characterized by many immune cell populations, reflecting the capacity of the immune system to sense tumor cells. Numerous studies have described the existence of naturally occurring tumor antigen (TA)-specific T-cell and B-cell responses, including TA-specific antibodies (Abs) (1) (2) (3) (4) (5) (6) . The role of T cells especially in the control and eradication of tumors has been largely documented (7, 8) . Notably, several clinical studies have demonstrated that a high density of tumor-infiltrating T cells is associated with an increased median survival of cancer patients (9, 10) . In contrast, the role played by the humoral immune response and B cells is still a matter of debate (11) (12) (13) (14) (15) . Although in mice many studies assigned B cells with a protumoral function, mainly based on the maintenance of a deleterious chronic inflammation (16) (17) (18) (19) , several studies in humans associated a high density of tumor-infiltrating B cells and plasma cells (PCs) with a favorable clinical outcome, and reported a positive correlation between the expression of B-cell related genes and disease-free survival (20) (21) (22) .
Previously, we described tertiary lymphoid structures (TLS) in non-small cell lung cancer (NSCLC) tumors, encompassing follicular B cells and clusters of DC-Lamp 1 mature dendritic cells (DCs) and T cells (23) . We showed that the density of DC-Lamp 1 mature DCs correlated with long-term survival of patients with early-stage NSCLC. TLS, initially described in autoimmune disorders, infectious diseases, and graft rejection (24) , are transient lymphoid structures induced on chronic inflammation in nonlymphoid tissues. In autoimmune diseases, the presence of TLS was associated with disease exacerbation and poor prognosis (25) , whereas during infection, T-and B-cell responses initiated in TLS were protective (26) . To date, studies understanding the role of TLS in the induction of a humoral immune response in human cancer are lacking.
In the present work, we fully characterize tumor-infiltrating B-cell subsets in NSCLC. We demonstrate that B-cell follicles in TLS present features of an ongoing humoral immune response, that a high follicular B-cell density is associated with longer survival in patients with NSCLC, and that the combination of follicular B-cell and mature DC densities further enhanced the prognostic value. Some of the results of this study have been previously reported as a poster during the 15th International Congress of Immunology in Milan, Italy (August 22-27, 2013) (27) .
Methods

Patients
A retrospective study was performed on formalin-fixed, paraffin-embedded NSCLC tumor samples, comprised of 74 untreated patients with early-stage NSCLC (see Table  E1 in the online supplement) and 122 patients with advanced-stage NSCLC, treated with neoadjuvant chemotherapy (see Table E2 ). Fresh tumor biopsies were retrieved from 61 patients with NSCLC for a prospective study. Nontumoral lymph nodes (LNs) were obtained from patients undergoing surgery for cardiac diseases. Peripheral blood was obtained from healthy volunteers. Additional details are provided in the online supplement.
Immunohistochemistry
Serial sections of paraffin-embedded NSCLC tumors were stained as previously described (28), using antigen retrieval conditions, Abs, and reagents listed in Table E3 . Single stainings were counterstained with hematoxylin.
Methods for Cell Quantification
Cell quantification was performed across whole tumor section. Mature DC quantification was determined as previously described (23) Mononuclear cells were isolated from fresh lung tumor specimens as previously described (28) . After cell sorting, total CD19
1 B cells were cultured in the presence of Pansorbin (Staphylococcus aureus cell extract; Merck, Darmstadt, Germany) and the supernatant (SN) was recovered every 3 days until Day 20 (see online supplement for details).
Flow Cytometry
Multiple stainings on isolated mononuclear cells were performed using Abs against B-cell markers (see Table E3 ), as previously described (28) .
TA Specificity
B-cell SN reactivity against a series of 33 TAs (see Table E4 ) was evaluated by ELISA, as previously described (29) . When possible, patient serum was also tested. Levels of TAbound IgG, IgA, IgD, IgE, and IgM were determined and expressed as reciprocal titers (see online supplement).
Statistical Analysis
Patients were stratified into two groups according to a high or low density of follicular B cells and mature DCs, using the "minimum P value" approach, which determines the cutoff value for the best separation of patients referring to their outcome (outcome-oriented approach), as previously described (see Figure E1 ) (30) . Groups of patients were appointed using the following cutoffs: 0.0255 mm 2 of follicular CD20
1 B cells/tumor IPF (fifth decile; see Figure E1A ) and 1.65 DC-Lamp 1 DCs/tumor IPF (third decile; see Figure  E1B ) for patients with early-stage NSCLC, 0.042 mm 2 of follicular CD20 1 B cells/ tumor IPF (sixth decile; see Figure E1C ) Figure E1D ) for patients with advanced-stage NSCLC. Disease-specific survival (DSS) curves were estimated by Kaplan-Meier method and differences between patient groups were calculated using the log-rank test, corrected using the formula proposed by Altman and coworkers (31) . Cox model was used for univariate analysis and differences between categories were calculated using the Wald test. A P value less than 0.05 was considered statistically significant. Additional details are provided in the online supplement.
Results
TLS Are Composed of the Same Contingent of Immune Cells as Secondary Lymphoid Organs
We previously reported the presence of TLS in human lung tumors, which we called tumor-induced bronchus-associated lymphoid tissues (23) . Because similar structures were afterward described in tissues other than lung and in several inflammatory pathologies, we now use the terminology used in the literature, namely TLS (32) . These TLS were mainly observed within tumor stroma, at the invasive margin of the tumor, and between tumor nests (see Figure E2 ). To study the role of the B-cell compartment within TLS, we first characterized immune cells surrounding B-cell follicles by immunohistochemistry ( Figure 1A ). As described in canonical lymphoid organs, we observed T-cell rich areas composed of clusters of CD3
1 T cells and DC-Lamp 1 mature DCs ( Figure 1B ), whereas most B cells, visualized with the mature B-cell marker CD20, segregated into follicles ( Figure 1C ). Many non-CD20 1 cells were also detectable within the B-cell follicles: few CD3 1 T cells ( Figure 1D ), a network of CD21 1 follicular DCs ( Figure 1E) , and a population of specialized CD68 1 macrophages (tingiblebody macrophages; Figure 1F ). These observations indicate that the presence and segregation of immune cells in TLS are the same as observed in secondary lymphoid organs, suggesting adaptive immune responses may take place within NSCLCassociated TLS.
B-Cell Areas of TLS Have Features of an Ongoing Humoral Immune Response
The segregation of T-and B-cell areas in secondary lymphoid organs is mandatory for the development of both high-affinity class-switched Abs and memory humoral immune responses. To determine if TLS could be sites for immune responses, we first assessed by immunohistochemistry B-cell differentiation stages in lung tumors, and compared it with secondary lymphoid organs. As in LN follicles (Figure 2A Figure 2N ), and in the stroma and fibrosis of the tumor (data not shown).
We further characterized and compared by flow cytometry intratumoral B-cell subsets with other anatomic sites, such as peripheral blood, LN, and nontumoral distant lung from patients with NSCLC and healthy donors (except for lung tissue). To visualize B cells we used here the pan-B cell marker CD19, expressed on all B-cell stages, whereas CD20 is known to be extinguished on PCs (33) . Fcreceptor-expressing cells, mainly CD14-positive monocytes and macrophages, were systematically excluded from the analysis to avoid false positives, using an anti-CD14 Ab. B-cell subsets were identified based on the differential expression of IgD and CD38 (34), including IgD 
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11 CD138 1 (more mature) PCs (35) . Every stage of B-cell differentiation was observed in tumors; however, their distribution was largely different from that in blood and LN from patients with NSCLC ( Figures 3A and 3B ). Memory B cells represented the predominant B-cell subset, irrespective of anatomic location. The second major population was naive B cells in blood and LN, whereas it was PCs in tumors ( Figure 3B ; 27.7, 17.2, and 7.5% of naive B cells and 1.5, 2.3, and 16.5% of PCs in blood, LNs, and tumors; absolute numbers for tumors are provided in Table E5 ). An intermediate distribution was observed in distant nontumoral lung, with equivalent percentages of naive B cells and PCs ( Figure 3B ; 8.8 and 10.6%, respectively). As opposed to what was observed in healthy donors, the ratio of naive/memory B cells was in favor of memory B cells in patients with NSCLC, both in blood and LNs (see Figure E3 ). No statistical difference was observed regarding GC-B cells between the different anatomic locations. The differential expression of additional markers (the activation marker CD23, the memory marker CD27, and the GC/centroblast marker CD77) allowed us to study the distribution of naive (Bm1 and Bm2), GC (Bm3 and Bm4), and memory (early Bm5 and late Bm5) B-cell subsets (34) in tumors compared with LNs from patients with NSCLC. Only a trend in favor of Bm1 versus Bm2 was seen in lung tumors versus LN ( Figure 3C ). Finally, we observed a significant correlation between the percentages of PCs and GC-B cells in fresh lung tumors (R = 0.5946; P = 0.0003) ( Figure 3D ) but also with the density of follicular B cells in the corresponding paraffin-embedded lung tumor sections (R = 0.5875; P = 0.0004) ( Figure 3E ), suggesting that most PCs were differentiated within NSCLC-associated TLS.
The presence of all B-cell differentiation stages in NSCLC tumors is in accordance with their in situ organization in TLS. Early-activated B cells undergo active proliferation in B-cell follicles where SHM and CSR machineries are activated, suggesting that TLS may be an active site for the generation of a humoral immunity.
Production of Tumor-Specific Abs by Intratumoral PCs
To determine whether tumor-infiltrating PCs may have a functional role in tumor recognition, we evaluated the capacity of their Abs to recognize common TAs known to elicit spontaneous immune responses in cancer patients (36) . SNs of B-cell cultures from 34 patients with NSCLC were analyzed by ELISA for IgG and IgA binding to a series of 33 TAs, including mostly cancer/testis antigens (NY-ESO-1, LAGE-1, MAGEs, SSXs, and so forth), mutational and stem-cell antigens (TP53, SOX2), endogenous retroviral antigens (GAG-HERV-K), along with a negative control antigen (DHFR) (see Table E4 ). Reactivity was detected against 21 out of the 33 TAs tested ( Figure 4A and Table 1 ). Some IgG reactive SNs also displayed IgA reactivity against the same TA (Table 1) . Over 41% of SNs (14 out of 34) displayed reactivity against at least one TA (Table 1) . Some SNs showed multiple antigen-specific IgG and IgA reactivity, such as P5, P11, and P22 with up to six to seven different TAs recognized. The most frequently recognized TAs were LAGE-1 (5 out of 14 SNs); then MAGEA1, MAGEC2, TP53 (3 out of 14 SNs); NY-ESO-1; and other MAGE antigens (MAGEA3 and MAGEA4, 2 out of 14 SNs). A low IgA reactivity against CT47 was observed in PBMC1 control SN. Reactivity against this TA has already been described in healthy donor sera (37) .
We further analyzed the strong reactivity observed for P22 SN against NY-ESO-1, by assessing its capacity to recognize a series of 17 overlapping peptides along the NY-ESO-1 molecule. The anti-NY-ESO-1 response was polyclonal, because at least three different areas of NY-ESO-1 molecule were recognized (Figures 4B and 4C) . Similar results were obtained with P21 SN, displaying reactivity against at least four different areas of TP53 molecule (see Figure  E4 ). Ab titers were observed as early as the third day of culture, and remained constant over time (Day 3-20 ; Figure 4C ). The reactivity observed in P22 SN against NY-ESO-1 ( Figures 4A and 4C) was mainly ascribed to a mixture of IgG and IgA but also IgM ( Figure 4D ). Next, we asked whether the antigen-specific Ab responses detected in primary tumors reflected overall seroreactivity from circulating blood. Two out of six patients had evidence of Abs against the same antigens in NSCLC SN and serum ( Figure 4E ).
In parallel, we analyzed the expression of the TAs in matched tumor samples by reverse transcriptase polymerase chain reaction (see online supplement). We observed a correlation between TA mRNA expression and IgG reactivity in two-thirds of the cases (data not shown).
Finally, we evaluated follicular B-cell densities in the paraffin-embedded tumors corresponding to the evaluated B-cell SN (stratification of patients according to the density of CD20
1 follicular B cells is detailed next). We observed that 44% (12 out of 27) of the SNs coming from tumors with high densities of follicular B cells displayed Ig reactivity against at least 1 out of 33 TAs tested, whereas only 29% (2 of 7) of the SNs coming from tumors with low follicular B-cell densities displayed an Ig reactivity (data not shown).
All together, these data demonstrate that TAs expressed by tumor cells are recognized by IgG and IgA-secreting PCs in the tumors.
Density of Follicular B Cells
Correlates with Long-Term Survival, and a Synergistic Effect Is Observed When Combined with Mature DC Density
Because the density of mature DCs was shown to be associated with a favorable prognosis in patients with NSCLC (23), we investigated correlations between follicular B-cell and mature DC densities, and whether they were associated with good clinical outcome ( Figure 5 ). Two independent patient cohorts were evaluated: 74 untreated patients with earlystage NSCLC (left column) and 122 patients with advanced-stage NSCLC treated with neoadjuvant chemotherapy (right column).
The global increase of follicular B-cell density was associated with an overall increase in mature DC density. Based on cutoffs determined by the minimum P value approach (see Figure E1) , we discriminated between patients with a high or a low density of follicular B cells and/or mature DCs. In the cohort of patients with earlystage NSCLC, 47% of patients (35 out of 74) were characterized as having a high density of both populations ("Foll-B/DC Hi Hi"), and 23% of patients (17 out of 74) a low density of both populations ("Foll-B/DC Lo Lo") ( Figures 5A and 5G) . Similar results were obtained in the advanced-stage NSCLC cohort, with 22% of "Foll-B/DC Hi Hi" patients (27 out of 122) and 39% "Foll-B/DC Lo Lo" patients (47 out of 122) ( Figures 5B and 5H) . However, the existence of "Foll B/DC mix" patients was observed in both cohorts: 17 "Foll-B/DC Lo Hi" patients and 5 "Foll-B/DC Hi Lo" patients (22 patients; 30%) in the earlystage NSCLC cohort ( Figures 5A and 5G) ; 25 "Foll-B/DC Lo Hi" patients and 23 "Foll-B/DC Hi Lo" patients (48 patients; 39%) in the advanced-stage NSCLC cohort ( Figures  5B and 5H) . In both cohorts, patient distribution within the different Foll-B and DC groups was not influenced by tumor histologic subtypes (Figures 5A and 5B ; see Tables E6-E9 ), suggesting that these parameters are independent.
The Kaplan-Meier curves indicated that "Foll-B Hi" patients have a prolonged survival as compared with "Foll-B Lo" patients (P = 0.04 for patients with earlystage NSCLC) ( Figure 5C ). The 4-year DSS rates were 97% among "Foll-B Hi" patients versus 62% among "Foll-B Lo" patients. A strong benefit in terms of survival was also observed for patients with advancedstage NSCLC, even if significance was not reached (median DSS = 56 mo for "Foll-B Hi" vs. 23 mo for "Foll-B Lo" patients; P = 0.06) ( Figure 5D ). The density of mature DCs was also associated with a favorable outcome in both cohorts (P = 0.003 in patients with early-stage NSCLC [ Figure 5E ], and P = 0.01 in treated patients with late-stage NSCLC [ Figure 5F ]).
We next combined the two immune populations. "Foll-B/DC Hi Hi" patients had the highest rate and median survival. One hundred percent of patients with early-stage NSCLC (P , 0.04) ( Figure 5G ), and 55% of treated patients with advancedstage NSCLC (P = 0.007) ( Figure 5H) were alive after a follow-up of 50 and 60 months, respectively. In contrast, "Foll-B/DC Lo Lo" patients had the worst rate and median survival. Only 38% of patients with earlystage NSCLC were alive after a follow-up of 50 months, with a median DSS of 42 months, and only 10% of patients with advanced-stage NSCLC were alive after a follow-up of 60 months, with a median DSS of 22 months. "Foll-B/DC mix" patients were at intermediate risk of death, with 82% and 42% of patients alive in earlystage and advanced-stage NSCLC cohorts, respectively.
These data were confirmed through cumulative impact analyses demonstrating no significant difference between patients who died from other causes than NSCLC in each group among each cohort (see Figure  E5) . By univariate analyses, we showed that the density of each immune cell type was highly associated with patient survival, and the combination of both biomarkers was the best predictor for survival, compared with standard clinical parameters (Tables 2  and 3 , for early-stage and advanced-stage NSCLC cohorts, respectively).
In conclusion, the density of these two antigen-presenting cell types is highly predictive of DSS in early-stage NSCLC and late-stage NSCLC, independently of the preoperative treatment received. More importantly, low densities of both follicular B cells and mature DCs allowed the identification of a group of patients with the worst clinical outcome.
Discussion
Numerous studies demonstrated in several cancer types that elevated immune cell infiltration correlates with a favorable clinical outcome (8) (9) (10) 38) . Previously, we extended this concept by describing for the first time the presence of TLS in the tumor stroma of patients with NSCLC (23) . We showed that these TLS were composed of mature DCs forming clusters with T cells, surrounded by B-cell follicles, and that a high TLS density of DCs correlated with longer survival in early-stage NSCLC. In the present study, we analyzed B-cell organization, differentiation, and prognostic impact in NSCLC. We first observed that follicular B cells included GC-B cells, characterized by a network of follicular DCs and Ki67 1 proliferating B cells. The expression of AID and Bcl6 suggests that SHM and CSR machineries are activated, processes that are required for the generation of effector and memory B cells after B-cell activation (39) . The presence of all B-cell stages, including CD38 
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2 GC-B cells, with a majority of memory B cells and variable percentages of PCs, was TA   SN  P5  P22  P11  P2  P28  P29  P21  P3  P6  P10  P15  P17  P27  P30  Total out of We evaluated whether the density of follicular B cells correlates with survival of patients with NSCLC, through two retrospective cohorts with distinct characteristics in terms of tumor stage and neoadjuvant treatment. In both cohorts, we demonstrated that a high density of follicular B cells was associated with an increase in the median survival. A positive correlation between B-cell numbers and clinical outcome was previously described in NSCLC (40) and in other cancer types, including primary cutaneous melanoma (41) and breast cancer (42) . However, these studies focused on individual tumorinfiltrating B-cell numbers. Here, we analyzed the density of follicular B cells, because it better reflects the initiation of a B-cell response. In that, our strategy parallels the recent work published by GuTrantien and coworkers (43) , who showed that tumor infiltration by CXCL13-producing CD4
1 follicular helper T cells, one of the major partners of follicular B cells in TLS, is associated with organized immune structures and long-term positive clinical outcome in breast cancer. Furthermore, the combination of follicular B-cell and mature DC densities allowed us to identify Foll-B/DC Hi Hi patients with prolonged survival and Foll-B/DC Lo Lo patients at high risk of death. We also observed that combined low densities of mature DCs and CD8 1 T cells also defined a group of patients with NSCLC with very poor clinical outcome (44) . Likewise, Nielsen and coworkers (45) demonstrated that the presence of both CD20
1 and CD8 1 tumor-infiltrating lymphocytes correlated with increased survival in highgrade serous ovarian cancer. In light of this study, our results strongly suggest that, in concert with mature DCs, follicular B cells could play a major role in the generation of protective cytolytic immune responses.
In parallel, we evaluated intratumoral B-cell functionality, with a particular focus on their capacity to produce anti-TA Abs. We showed that ex vivo cultured B cells were able to produce high levels of IgG and IgA, and that the IgG and IgA produced displayed reactivity against several wellknown TAs. Sera reactivities against TAs have been described in many cancer types, such as anti-NY-ESO-1 Abs in sarcoma (46) and primary breast cancer (1), anti-XAGE-1b Abs in NSCLC (3), anti-NY-ESO-1, anti-LAGE1, and anti-P53 Abs in ovarian cancer (37, 45) , but the specificity of Abs secreted by tumorinfiltrating B cells has been less investigated. Here, we showed that approximately half of the patients with NSCLC evaluated had developed Ab reactivity against up to seven different TAs, where we identified LAGE-1 as the most immunogenic TA in NSCLC, followed by MAGE family antigens, P53, and NY-ESO-1. In some patients, reactivity against the same TA or additional TAs could be observed in the serum. In addition, the correlations observed in our study between the percentage of PCs and the percentage of GC-B cells in the tumor or the density of follicular B cells in the tumor section strongly suggest that these immunoglobulin-secreting PCs do not come from the periphery but were generated in TLS, after in situ antigendriven B-cell activation. The work of Cipponi and coworkers (47) , who identified a series of tumor B-cell clones defined by clonal amplification, SHM, and CSR in metastatic lesions of melanoma, is in accordance with that hypothesis. Finally, a very recent study also pointed out the role 0 to infinity NA Definition of abbreviations: ADC = adenocarcinoma; DC = dendritic cell; Foll-B = follicular B cell; NA = not applicable (because of a lack of events in one group of patients); SCC = squamous cell carcinoma. The Cox model was used for univariate analysis. A P value less than 0.05 was considered statistically significant (bold).
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of tumor-infiltrating PCs in NSCLC, by demonstrating the existence of a positive correlation between IgkC expression and longer survival (48) .
The existence of such a humoral immune response in some patients with NSCLC opens the way to the development of new vaccine-and antibody-based therapeutic strategies. Several studies reported the development of both humoral and cellular specific immune responses in NY-ESO-1-vaccinated cancer patients (49, 50) . In mice, Noguchi and coworkers (51) demonstrated the antitumor effect of an anti-NY-ESO-1 Ab when associated with chemotherapy. They observed not only the generation of an anti-NY-ESO-1 CD8 immune response, but also the differentiation of other antigen-specific
CD8
1 T cells, thanks to antigen spreading and DC activation by anti-NY-ESO-1 immune complex. Formation of anti-TA immune complex, Fc-g receptor engagement on DC, and antigen-specific CD8 1 T-cell generation (52) could then be one of the main mechanisms underlying TLS B-cell-mediated protective immunity.
In conclusion, we demonstrated that the organization of intratumoral B cells into B-cell follicles is associated with the development of antigen-specific humoral responses, with the emergence of PCs secreting TA-specific immunoglobulins, allowing the identification of new therapeutic targets in NSCLC. In addition, we demonstrated for the first time that the density of follicular B cells is highly predictive of survival in NSCLC, and low densities of both CD20 Definition of abbreviations: ADC = adenocarcinoma; CDDP = cisplatin; DC = dendritic cell; Foll-B = follicular B cell; GC = gemcitabine cisplatin; NA = not applicable (because of a lack of events in one group of patients); ND = not determined; SCC = squamous cell carcinoma; TAX = taxotere; VIN = vinorelbine. The Cox model was used for univariate analysis. A P value less than 0.05 was considered statistically significant (bold).
